Sumitomo Pharma
Sumitomo Pharma Co., Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1897, the company has a rich history marked by significant milestones, including advancements in research and development that have positioned it as a leader in innovative healthcare solutions. Specialising in prescription pharmaceuticals, Sumitomo Pharma focuses on areas such as central nervous system disorders, oncology, and regenerative medicine. Its unique approach to drug development, emphasising both quality and efficacy, has led to the creation of several groundbreaking therapies. With a strong market presence and a commitment to improving patient outcomes, Sumitomo Pharma continues to achieve notable recognition within the industry, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Sumitomo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sumitomo Pharma's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sumitomo Pharma's reported carbon emissions
In 2023, Sumitomo Pharma reported total carbon emissions of approximately 383,484,000 kg CO2e, comprising 26,827,000 kg CO2e from Scope 2 and 356,214,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 42% reduction in absolute Scope 1 and 2 emissions by FY2030 from a FY2020 baseline. Additionally, it aims to cut Scope 3 emissions from purchased goods and services by 25% within the same timeframe. Over the past few years, Sumitomo Pharma's emissions have shown fluctuations. In 2022, the company reported approximately 39,869,000 kg CO2e in Scope 2 and 364,869,000 kg CO2e in Scope 3 emissions. In 2021, these figures were about 40,351,000 kg CO2e for Scope 2 and 382,293,000 kg CO2e for Scope 3. The data indicates a focus on reducing emissions, particularly in Scope 2 and 3 categories, which are critical for the pharmaceutical sector. Sumitomo Pharma's commitments align with the Science Based Targets initiative (SBTi), ensuring that their reduction targets are consistent with the global goal of limiting temperature rise to 1.5°C. The company is currently classified as a near-term target setter, with its targets reflecting a proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 41,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 38,906,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 35,270,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sumitomo Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
